Last reviewed · How we verify
NCT06176040
A Study of TAVO101 in Atopic Dermatitis Patients
Phase 2 trial testing TAVO101 in Atopic Dermatitis in 20 participants. Participants enrolled and being followed up; not accepting new ones.
15 March 2025
Quick facts
| Lead sponsor | Tavotek Biotherapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 15 March 2024 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 June 2025 |
| Sites | 2 locations across New Zealand, Australia |
Drugs / interventions tested
- TAVO101 — full drug profile →
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Tavotek Biotherapeutics — full company profile →
Who can join
Adults 18 to 75, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2 pilot study to examine the preliminary efficacy, safety and PK of TAVO101 in adult patients with moderate and severe AD.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Emerging Systemic Treatment Options in Atopic Dermatitis.
Salman A, Giménez-Arnau AM. · · 2024 · cited 3× · PMID 38966900 · DOI 10.4274/balkanmedj.galenos.2024.2024-5-78 -
Potential of alarmin-targeted bispecific and combination therapies in airway disease.
Komori HK, Ortega H. · · 2025 · PMID 41409758 · DOI 10.3389/falgy.2025.1700060
Verify or expand the search:
- PubMed search for NCT06176040
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Tavotek Biotherapeutics trials
Trials by the same sponsor.
- NCT06761651 — A Study of TAVO412 in Patients with Cancer (TAVO412) · Phase 1 · recruiting
- NCT05548634 — A Study of TAVO412 in Patients with Cancer · Phase 1 · active not recruiting
- NCT05298046 — Study of TAVO101 in Healthy Volunteers · Phase 1 · completed
- NCT05313152 — Study of TAVO103A in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06176040 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tavotek Biotherapeutics
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06176040.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing